{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T22:30:36Z","timestamp":1781735436249,"version":"3.54.5"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.cmi.2025.08.028","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:15:52Z","timestamp":1756826152000},"page":"251-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Decoding COVID-19: phenotypes and the pursuit of precision medicine"],"prefix":"10.1016","volume":"32","author":[{"given":"Sias J.","family":"Scherger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anum","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre C.","family":"Kalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.08.028_bib1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.08.028_bib2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/humu.22080","article-title":"Deep phenotyping for precision medicine","volume":"33","author":"Robinson","year":"2012","journal-title":"Hum Mutat"},{"key":"10.1016\/j.cmi.2025.08.028_bib3","first-page":"406","article-title":"Sepsis phenotypes, subphenotypes, and endotypes: are they ready for bedside care?","volume":"30","author":"Scherger","year":"2024","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.cmi.2025.08.028_bib4","doi-asserted-by":"crossref","DOI":"10.1186\/bcr1639","article-title":"Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients","volume":"9","author":"Dunnwald","year":"2007","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.cmi.2025.08.028_bib5","doi-asserted-by":"crossref","unstructured":"Li P, Zhao H, Zhang J, Ning Y, Tu Y, Xu D, et al. Similarities and differences between HFmrEF and HFpEF. Front Cardiovasc Med. 202:678614. DOI:https:\/\/doi:10.1186\/bcr1639.","DOI":"10.1186\/bcr1639"},{"key":"10.1016\/j.cmi.2025.08.028_bib6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1001\/jamainternmed.2020.3539","article-title":"Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy","volume":"180","author":"Grasselli","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cmi.2025.08.028_bib7","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00134-020-06120-4","article-title":"Clinical phenotypes of critically ill COVID-19 patients","volume":"46","author":"Azoulay","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2025.08.028_bib8","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1080\/17476348.2021.1960824","article-title":"COVID-19 clinical phenotypes and short-term outcomes: differences between the first and the second wave of pandemic in Italy","volume":"15","author":"Portacci","year":"2021","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.cmi.2025.08.028_bib9","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S1473-3099(21)00019-0","article-title":"Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study","volume":"21","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.028_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0248956","article-title":"Characterizing COVID-19 clinical phenotypes and associated comorbidities and complication profiles. Lazzeri C, editor","volume":"16","author":"Lusczek","year":"2021","journal-title":"PLOS ONE"},{"key":"10.1016\/j.cmi.2025.08.028_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmedinf.2023.105286","article-title":"Longitudinal dynamic clinical phenotypes of in-hospital COVID-19 patients across three dominant virus variants in New York","volume":"181","author":"Ho","year":"2024","journal-title":"Int J Med Inf"},{"key":"10.1016\/j.cmi.2025.08.028_bib12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.chest.2023.09.020","article-title":"Using trajectories of bedside vital signs to identify COVID-19 subphenotypes","volume":"165","author":"Bhavani","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2025.08.028_bib13","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s10067-020-05569-4","article-title":"Haemophagocytic syndrome and COVID-19","volume":"40","author":"Retamozo","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.cmi.2025.08.028_bib14","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3390\/v16071004","article-title":"Macrophage activation syndrome in viral sepsis","volume":"16","author":"Papageorgiou","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.cmi.2025.08.028_bib15","doi-asserted-by":"crossref","first-page":"e754","DOI":"10.1016\/S2665-9913(20)30343-X","article-title":"Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study","volume":"2","author":"Webb","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.cmi.2025.08.028_bib16","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2665-9913(21)00140-5","article-title":"Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study","volume":"3","author":"Hsu","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.cmi.2025.08.028_bib17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/08850666221131265","article-title":"Assessment of admission COVID-19 associated hyperinflammation syndrome score in critically-ill COVID-19 patients","volume":"38","author":"Yildirim","year":"2023","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.cmi.2025.08.028_bib18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13613-024-01319-w","article-title":"Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron sublineage JN.1 in critically ill COVID-19 patients: a prospective, multicenter cohort study in France, November 2022 to January 2024","volume":"14","author":"de Prost","year":"2024","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.cmi.2025.08.028_bib19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cmi.2025.08.028_bib20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.cmi.2025.08.028_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.910516","article-title":"Chasing the ghost: hyperinflammation does not cause sepsis","volume":"13","author":"Shapiro","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cmi.2025.08.028_bib22","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.jaci.2021.03.047","article-title":"Distinct cytokine profiles associated with COVID-19 severity and mortality","volume":"147","author":"Dorgham","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.cmi.2025.08.028_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/rmv.2141","article-title":"Interleukin-6 in Covid-19: a systematic review and meta-analysis","volume":"30","author":"Coomes","year":"2020","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.cmi.2025.08.028_bib24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1684\/ecn.2020.0448","article-title":"Interleukin-6 and severe COVID-19: a systematic review and meta-analysis","volume":"31","author":"Mojtabavi","year":"2020","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.cmi.2025.08.028_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2418","article-title":"Anakinra was not associated with lower mortality in hospitalised COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials","volume":"33","author":"Shang","year":"2023","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.cmi.2025.08.028_bib26","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with Covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.08.028_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107602","article-title":"The effect of tocilizumab on COVID-19 patient mortality: a systematic review and meta-analysis of randomized controlled trials","volume":"96","author":"Lin","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.cmi.2025.08.028_bib28","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"Abani","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.cmi.2025.08.028_bib29","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.08.028_bib30","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cmi.2023.12.028","article-title":"Choosing immunomodulating therapies for the treatment of COVID-19: Recommendations based on placebo-controlled trial evidence","volume":"30","author":"Sweeney","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.08.028_bib31","doi-asserted-by":"crossref","DOI":"10.1097\/CCM.0000000000006526","article-title":"Baricitinib: the immunomodulator of choice for severe COVID-19\u2014the verdict is in","volume":"53","author":"Kalil","year":"2025","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2025.08.028_bib32","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/jama.2023.11043","article-title":"Abatacept, cenicriviroc, or infliximab for treatment of adults hospitalized with COVID-19 pneumonia: a randomized clinical trial","volume":"330","author":"O\u2019Halloran","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2025.08.028_bib33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.2023.11260","article-title":"Translating clinical trial results to clinical practice during a pandemic","volume":"330","author":"Kalil","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2025.08.028_bib34","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamainternmed.2020.3313","article-title":"Is a \u201ccytokine storm\u201d relevant to COVID-19?","volume":"180","author":"Sinha","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cmi.2025.08.028_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.156006","article-title":"Proinflammatory cytokines levels in sepsis and healthy volunteers, and tumor necrosis factor-alpha associated sepsis mortality: a systematic review and meta-analysis","volume":"158","author":"Gharamti","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.cmi.2025.08.028_bib36","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Del Valle","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2025.08.028_bib37","article-title":"Multi-cohort study on cytokine and chemokine profiles in the progression of COVID-19","volume":"14","author":"Huang","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2025.08.028_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe3024","article-title":"Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm","volume":"6","author":"Mudd","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.cmi.2025.08.028_bib39","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cmi.2025.08.028_bib40","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S2213-2600(21)00384-2","article-title":"Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Kalil","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2025.08.028_bib41","doi-asserted-by":"crossref","unstructured":"Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T Cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020 1;11:827. https:\/\/doi.org\/10.3389\/fimmu.2020.00827.","DOI":"10.3389\/fimmu.2020.00827"},{"key":"10.1016\/j.cmi.2025.08.028_bib42","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","article-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.cmi.2025.08.028_bib43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijid.2020.04.086","article-title":"Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis","volume":"96","author":"Zhao","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.028_bib44","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.3390\/ijms23073636","article-title":"Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases","volume":"23","author":"Buonacera","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cmi.2025.08.028_bib45","first-page":"e6","article-title":"Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19","volume":"81","author":"Liu","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.cmi.2025.08.028_bib46","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.3390\/biomedicines9111656","article-title":"Dynamic changes of the neutrophil-to-lymphocyte ratio, systemic inflammation index, and derived neutrophil-to-lymphocyte ratio independently predict invasive mechanical ventilation need and death in critically ill COVID-19 patients","volume":"9","author":"Moisa","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.cmi.2025.08.028_bib47","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12916-020-01673-z","article-title":"New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis","volume":"18","author":"Hou","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.cmi.2025.08.028_bib48","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.3390\/genes14091798","article-title":"Polymorphisms within the SARS-CoV-2 human receptor genes associate with variable disease outcomes across ethnicities","volume":"14","author":"Adimulam","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.cmi.2025.08.028_bib49","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.3390\/v15091784","article-title":"Innate immune gene polymorphisms and COVID-19 prognosis","volume":"15","author":"Bakaros","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.cmi.2025.08.028_bib50","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9082455","article-title":"Inflammasome genetic variants are associated with protection to clinical severity of COVID-19 among patients from Rio de Janeiro, Brazil","volume":"2022","author":"De S\u00e1","year":"2022","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.cmi.2025.08.028_bib51","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.cell.2020.08.001","article-title":"Severe COVID-19 is marked by a dysregulated myeloid cell compartment","volume":"182","author":"Schulte-Schrepping","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cmi.2025.08.028_bib52","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.cell.2020.08.002","article-title":"Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19","volume":"182","author":"Silvin","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cmi.2025.08.028_bib53","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.cell.2020.10.037","article-title":"Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19","volume":"183","author":"Su","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cmi.2025.08.028_bib54","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1126\/science.abc6261","article-title":"Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans","volume":"369","author":"Arunachalam","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cmi.2025.08.028_bib55","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41392-021-00749-3","article-title":"SARS-CoV-2 infection causes immunodeficiency in recovered patients by downregulating CD19 expression in B cells via enhancing B-cell metabolism","volume":"6","author":"Jing","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.cmi.2025.08.028_bib56","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.3390\/cells14141093","article-title":"Evolution of blood innate immune cell phenotypes following SARS-CoV-2 infection in hospitalized patients with COVID-19","volume":"14","author":"Dendooven","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.cmi.2025.08.028_bib57","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.3466","article-title":"Are all cytokine storms born equal?","volume":"8","author":"Kalil","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cmi.2025.08.028_bib58","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3390\/ijms20030649","article-title":"Interleukin-18 in health and disease","volume":"20","author":"Yasuda","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cmi.2025.08.028_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.789462","article-title":"SARS-CoV-2 spike antagonizes innate antiviral immunity by targeting interferon regulatory factor 3","volume":"11","author":"Freitas","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.cmi.2025.08.028_bib60","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2024.2361019","article-title":"SARS-CoV-2 infection induces adaptive NK cell responses by spike protein-mediated induction of HLA-E expression","volume":"13","author":"Hasan","year":"2024","journal-title":"Emerg Microbe Infect"},{"key":"10.1016\/j.cmi.2025.08.028_bib61","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41586-021-04352-y","article-title":"Evolution of enhanced innate immune evasion by SARS-CoV-2","volume":"602","author":"Thorne","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2025.08.028_bib62","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/s41594-020-0511-8","article-title":"SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation","volume":"27","author":"Schubert","year":"2020","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.cmi.2025.08.028_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111892","article-title":"SARS-CoV-2 escapes direct NK cell killing through Nsp1-mediated downregulation of ligands for NKG2D","volume":"41","author":"Lee","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.cmi.2025.08.028_bib64","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.1038\/s41467-021-26910-8","article-title":"SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis","volume":"12","author":"Yoo","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2025.08.028_bib65","article-title":"SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to down-regulate MHC-I surface expression","volume":"120","author":"Arshad","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cmi.2025.08.028_bib66","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00402-21","article-title":"Contribution of SARS-CoV-2 accessory proteins to viral pathogenicity in K18 human ACE2 transgenic mice","volume":"95","author":"Silvas","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/j.cmi.2025.08.028_bib67","doi-asserted-by":"crossref","DOI":"10.1007\/s00134-025-07828-x","article-title":"Subphenotypes and phenotypes to resolve sepsis heterogeneity: Hype or hope?","author":"Kalil","year":"2025","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2025.08.028_bib68","doi-asserted-by":"crossref","first-page":"489","DOI":"10.12788\/jhm.3497","article-title":"Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19","volume":"15","author":"Keller","year":"2020","journal-title":"J Hosp Med"},{"key":"10.1016\/j.cmi.2025.08.028_bib69","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1097\/CCM.0000000000005983","article-title":"Analysis of protein biomarkers from hospitalized COVID-19 patients reveals severity-specific signatures and two distinct latent profiles with differential responses to corticosteroids\u2217","volume":"51","author":"Verhoef","year":"2023","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2025.08.028_bib70","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1080\/07391102.2020.1792992","article-title":"Identification of potential drugs against SARS-CoV-2 non-structural protein 1 (nsp1)","volume":"39","author":"de Lima Menezes","year":"2021","journal-title":"J Biomol Struct Dyn"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25004264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25004264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T16:49:51Z","timestamp":1768841391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25004264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1198743X25004264"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.08.028","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decoding COVID-19: phenotypes and the pursuit of precision medicine","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}